Loading patent…
AssigneeCellectis
InventorsRoman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Estimating the term…
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
A population of isolated primary human T cells comprising at least 105 isolated primary human T cells that express a chimeric antigen receptor (CAR) with a 4-1BB intracellular activation domain and have at least one PD1 allele inactivated;
Dependencies are inferred from the claim text.